

ASX ANNOUNCEMENT

Thursday 17 July 2025

IDT Signs Agreement with NASDAQ-Listed Gelteq to Establish Dedicated Product Development & Manufacturing Facility

IDT Australia Limited (ASX: IDT) (IDT or the **Company**), a leading pharmaceutical contract development and manufacturing organisation (**CDMO**), is pleased to announce the signing of a Memorandum of Understanding (**MoU**) with Gelteq Limited (**NASDAQ: GELS**) for a dedicated, Australian-based manufacturing facility to support the development and scale up of Gelteq's gel-based products across diverse global pharmaceutical, nutraceutical and animal health markets.

Gelteq is a Nasdaq-listed clinical and science-based company focused on developing and commercialising white label ingestible gel-based solutions for prescription drugs, nutraceuticals, pet care, sports and other products. Its innovative delivery platform is designed to provide an easier administration of oral drugs and supplements in humans and animals.

The MoU establishes a framework for Gelteq to set up its base and develop a dedicated facility within IDT's GMP manufacturing site, and both parties anticipate a final binding agreement to be in place in the coming months.

Highlights of the Agreement:

- **Facilities and Equipment** required for the manufacture of Gelteq products, in a dedicated building and purpose-built facility funded by Gelteq, with trained staff and operational support.
- **Compliance and Certification** necessary for products in the therapeutic, veterinary and nutraceutical markets across various product presentations, including regulatory requirements, permits, and licenses that comply with APVMA, FDA, and TGA standards.
- **Rapid Scale Up Capability** to integrate additional manufacturing space and equipment to support growth.

This partnership will position IDT at the forefront of an innovative drug delivery platform not currently available in Australia for pharmaceuticals, expanding its suite of advanced delivery technologies for clients. With Gelteq onsite as an integral part of IDT, it equips IDT with access to enhanced capabilities, strengthens its market differentiation, and creates opportunities for collaboration, new revenue streams, and unique client offerings, reinforcing its reputation as a leader in pharmaceutical innovation.

About IDT

IDT (ASX:IDT) is an Australian pharmaceutical manufacturing company based in Boronia, Victoria, Australia. The Company has extensive experience in the development and production of high potency and high containment pharmaceutical products for local and international clients. IDT's facilities are cGMP compliant and are regularly audited by the US FDA and Australian TGA. With an experienced team of specialists within world-class facilities, IDT provides a full-scale service for new drug development and scale-up, commercial active drug manufacture as well as a variety of oral and injectable finished drug dose forms.

Nathan Givoni, the Chief Executive Officer of Gelteq, said:

“Partnering with IDT to establish a locally-based, purpose-built manufacturing facility strategically positions Gelteq to accelerate and scale our products for the global nutraceutical, pharmaceutical and animal health markets. IDT not only brings proven development, manufacturing and regulatory expertise to support our goals, but also a unique knowledge base to speed up the development of new products targeting these markets.”

Paul McDonald, the Chief Executive Officer of IDT Australia, said:

“We are excited to combine our proven development and manufacturing capabilities with Gelteq’s innovative delivery system for wellness and therapeutic products. Gelteq’s proprietary gel technologies offer distinct benefits in both delivery and combination therapy opportunities needed to improve care and dosing compliance across many end markets.”

Ends.../

Authorised by the Board of Directors of IDT Australia Limited.

For investor and media enquiries, please contact:

Brendon Lau

E: brendon@vantagepointpartners.com.au

M: +61 409 341 613

Forward-looking statements

This announcement contains or may contain forward-looking statements that are based on IDT Australia’s beliefs, assumptions, and expectations and on information currently available to IDT Australia.

All statements that address operating performance, events, or developments that IDT Australia or its directors expect or anticipate will occur in the future are forward-looking statements, including, without limitation, statements as to the expectations of IDT Australia or the market it operates in.

IDT Australia believes that these forward-looking statements are reasonable as and when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. IDT Australia does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. No assurance or guarantee is, or should be taken to be, given in relation to, and no reliance should be placed on, the future business performance or results of IDT Australia or the likelihood that the current assumptions, estimates or outcomes will be achieved. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements

About IDT

IDT (ASX:IDT) is an Australian pharmaceutical manufacturing company based in Boronia, Victoria, Australia. The Company has extensive experience in the development and production of high potency and high containment pharmaceutical products for local and international clients. IDT’s facilities are cGMP compliant and are regularly audited by the US FDA and Australian TGA. With an experienced team of specialists within world-class facilities, IDT provides a full-scale service for new drug development and scale-up, commercial active drug manufacture as well as a variety of oral and injectable finished drug dose forms.

For personal use only